Review Article
Stress CMR in Known or Suspected CAD: Diagnostic and Prognostic Role

Francesca Baessato, Marco Guglielmo, Giuseppe Muscogiuri, Andrea Baggiano, Laura Fusini, Stefano Scafuri, Mario Babbaro, Rocco Mollace, Ada Collevecchio, Andrea Guaricci, and Gianluca Pontone

1Department of Cardiology, San Maurizio Regional Hospital, Bolzano, Italy
2Cardiovascular Imaging Department, Centro Cardiologico Monzino IRCCS, Milan, Italy
3Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy
4Institute of Cardiovascular Disease, Department of Emergency and Organ Transplantation, University Hospital Policlinico of Bari, Bari, Italy

Correspondence should be addressed to Gianluca Pontone; gianluca.pontone@cardiologicomonzino.it

Received 30 October 2020; Revised 23 December 2020; Accepted 4 January 2021; Published 15 January 2021

Copyright © 2021 Francesca Baessato et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The recently published 2019 guidelines on chronic coronary syndromes (CCS) focus on the need for noninvasive imaging modalities to accurately establish the diagnosis of coronary artery disease (CAD) and assess the risk of clinical scenario occurrence. Appropriate patient management should rely on controlling symptoms, improving prognosis, and guiding each therapeutic strategy as well as monitoring disease progress. Among the noninvasive imaging modalities, cardiovascular magnetic resonance (CMR) has gained broad acceptance in past years due to its unique features in providing a complete assessment of CAD through data on cardiac anatomy and function and myocardial viability, with high spatial and temporal resolution and without ionizing radiation. In detail, evaluation of the presence and extent of myocardial ischemia through stress CMR (S-CMR) has shown a high rule-in power in detecting functionally significant coronary artery stenosis in patients suspected of CCS. Moreover, S-CMR technique may add significant prognostic value, as demonstrated by different studies which have progressively evidenced the valuable power of this multiparametric imaging modality in predicting adverse cardiac events. The latest scientific progress supports a greater expansion of S-CMR with improvement of quantitative myocardial perfusion analysis, myocardial strain, and native mapping within the same examination. Although further study is warranted, these techniques, which are currently mostly restricted to the research field, are likely to become increasingly prevalent in the clinical setting with the scope of increasing accuracy in the selection of patients to be sent to invasive revascularization. This review investigates the diagnostic and prognostic role of S-CMR in the context of CAD, by analysing a strong, long-standing, scientific evidence together with an appraisal of new advanced techniques which may potentially enrich CAD management in the next future.

1. Introduction

Coronary artery disease (CAD) is a widespread clinical phenomenon associated with different clinical entities, which involves a large burden on the healthcare system with an increasing need for objective diagnostic tests to both confirm the diagnosis and assess the event risk [1–4]. In 2019, the European Society of Cardiology (ESC) published the guidelines on the diagnosis and management of chronic coronary syndromes (CCS), which represent a relevant step by introducing innovative changes mostly in the diagnostic workup of suspected obstructive CAD. Noninvasive imaging methods, either functional tests or anatomical imaging, represent indispensable tools for appropriate management of patients with known or suspected CAD, by providing adequate detection of the disease, guiding therapy, and predicting outcome. Stress CMR (S-CMR) is a functional imaging test that has been widely recognized in the past few years as an accurate, well-
validated, nonionizing technique [5–7]. The possibility of a multiparametric approach in each S-CMR study, from reproducible evaluation of cardiac function and scar detection to an accurate definition of myocardial ischemia in hemodynamically relevant coronary stenosis and microvascular dysfunction, has made S-CMR an appealing noninvasive modality for comprehensive assessment of CAD.

2. Clinical Applications and Technical Approach

According to the latest version of the guidelines, the diagnostic approach of CAD should be primarily based on the clinical likelihood of the disease, and the choice for the initial diagnostic test, either noninvasive imaging as a “gatekeeper” to invasive coronary angiography (ICA) or direct ICA, should be based on clinical risk assessment, patient characteristics, local expertise, and test availability [8].

Noninvasive imaging methods, either functional tests, such as S-CMR, or anatomical imaging, such as cardiac computed tomography angiography (CCTA), are recommended in Class Ib as the initial tests for diagnosing CAD in symptomatic patients in whom obstructive CAD cannot be excluded by clinical assessment alone [9]. Of note, each imaging test has a different performance in ruling in or ruling out obstructive CAD, which should also be taken into account in the initial workup.

Functional imaging methods include myocardial perfusion imaging with single-photon emission computed tomography (SPECT), positron emission computed tomography (PET), stress echocardiography, and S-CMR. These modalities, although possibly missing subclinical atherosclerosis, typically have better rule-in power and have shown higher specificity for the detection of hemodynamically significant coronary stenosis than anatomical imaging with CCTA, by leading to fewer referrals for ICA compared with a strategy relying on anatomical imaging or exercise ECG only [10].

S-CMR can detect myocardial ischemia, thus functionally significant CAD, through evaluation of perfusion defects or ischemic wall motion abnormalities (WMA) provoked by exercise or pharmacological stress. S-CMR protocol should be performed according to the latest update of the S-CMR guidelines [11] and briefly implies a rest and stress phase, with final late gadolinium enhancement (LGE) sequences.

Vasodilators are the most commonly used stress agents (adenosine, dipyridamole, and regadenoson) which commonly induce myocardial ischemia through a “steal phenomenon” and loss of autoregulation mechanism, thus leading to perfusion defects [12]. In case of perfusion imaging, a first-pass perfusion technique using a saturation-prepared T1-weighted fast gradient echo sequence is performed at peak myocardial stress during contemporary gadolinium contrast agent injection. If dipyridamole is used, additional cine sequences are exploited due to its longer half-life [13].

In opposition, inotropic agents, such as dobutamine, act by improving heart rate and only cine sequences are acquired at maximal stress for detection of regional WMA to unmask myocardial ischemia. Hence, each S-CMR examination can be classified as either normal (absence of stress perfusion defect in at least 1 myocardial segment free from LGE) or positive for ischemia (reversible myocardial perfusion defect alone or combined with WMA in at least 1 myocardial segment without corresponding LGE, as shown in Figure 1).

Actually, the recent 2019 guidelines recommend S-CMR (Class Ib) preferentially in patients with higher clinical likelihood of CAD or with a history of revascularization, in whom a functional evaluation of ischemia together with myocardial viability would be most useful, as also supported by cost-effectiveness data [14]. On the other hand, anatomical imaging with CCTA is recommended as first-line test (Class Ib) in suitable patients with low to intermediate clinical likelihood of CAD or no history of CAD, due to its highest rule-out capability [9].

This represents a relevant change compared to the previous version of the guidance, where stress imaging was recommended in patients with stable CAD as the first preferred diagnostic option (Class Ib), while CCTA was given only a Class IIa indication as an alternative test for ruling out significant CAD in selected patients [15].

If recent strong evidences [16, 17] have favoured in Europe a relevant spin-off of CCTA in the field of CCS against functional imaging [18, 19], numerous data have underlined the excellent sensitivity and specificity of S-CMR in CAD diagnosis and patient risk classification with a long-standing scientific evidence [20, 21].

3. Diagnostic Role of Stress CMR

Numerous studies have reported a high diagnostic accuracy of noninvasive imaging modalities in detecting significant obstructive CAD against clinical gold standards, angiographically determined luminal coronary stenosis and fractional flow reserve (FFR) [22–28].

Concerning S-CMR, there is a wide body of scientific evidence that has strengthened its position, and S-CMR has shown excellent diagnostic performance in the detection of CAD, both for hemodynamically significant coronary stenosis and microvascular dysfunction [29, 30]. Many of these studies regarding the diagnostic performance of S-CMR are listed in Table 1.

In 2001, Schwitter et al. presented one of the first multi-slice approach studies on perfusion S-CMR in an unselected study population and demonstrated for S-CMR a sensitivity and specificity of 91% and 94%, respectively, for the detection of CAD by S-CMR using PET as gold standard, and a sensitivity and specificity of 87% and 85%, respectively, using quantitative coronary angiography (stenosis > 50%) as gold standard [31]. These results initially sustained the role of perfusion CMR as a reliable modality for the detection of CAD in comparison to other perfusion modalities, with the additional capacity of identifying even subendocardial defects, which are currently missed by SPECT.

A large meta-analysis by Nandalur et al. involving 1183 patients further enhanced the emerging role of S-CMR in the diagnosis of CAD by showing a sensitivity of 91% and a specificity of 81% for perfusion CMR and a sensitivity of 83% and specificity of 86% for stress-induced WMA in a per patient analysis, respectively [32].
Figure 1: Continued.
Different trials investigated the diagnostic accuracy of S-CMR versus SPECT, a still worldwide used technique that historically has represented the gold standard for myocardial perfusion assessment.

The MR-IMPACT trial in 2008 was a multicentre, multi-vendor, randomized trial that determined in 241 patients the diagnostic performance of adenosine perfusion-CMR in comparison to SPECT for the detection of CAD, with ICA as the reference standard. Perfusion-CMR at the optimal contrast dose had similar performance as SPECT studies in patients with the same dose (area under ROC curve (AUC): 0.86 ± 0.06 vs. 0.75 ± 0.09 for SPECT, p = 0.12), but with even superior diagnostic performance when compared to the entire SPECT population (AUC: 0.67 ± 0.05, n = 212; p = 0.013). Schwitter et al. were therefore able to demonstrate how S-CMR could at least represent a valuable alternative to SPECT for CAD detection [33].

These evidences were later supported by the larger MR-IMPACT II trial, which involved 533 patients among 33 centres. Patients were evaluated by S-CMR and gated-SPECT before ICA. Both tests showed a nonsignificant difference in terms of percentage of not-evaluable tests (5.6% versus 3.7%, respectively, p = 0.21) while S-CMR showed a superior sensitivity in detecting CAD compared to SPECT (sensitivity score of 0.69 and 0.59, respectively, p = 0.024), but with a lower specificity (specificity scores of 0.61 and 0.72, respectively, p = 0.038) [34]. The overall superiority of S-CMR over SPECT and gated-SPECT for the detection of CAD was demonstrated (AUC 0.75 vs. 0.65 vs. 0.69) with significant difference (p = 0.0004 and p = 0.018) [35].

Of note, MR-IMPACT trials were performed on a selected population with a relatively high pretest probability of disease, which is not the typical population referred for noninvasive stress tests in clinical practice. However, all tests were performed in all patients to avoid testing bias.

A powerful and direct comparison between S-CMR and SPECT was additionally provided by the CE-MARC study in 2012. This was a large, prospective, multicentre trial that involved a cohort of 628 patients with suspected angina, who prospectively underwent S-CMR, SPECT, and ICA (reference standard) examinations in a period of 4 weeks with later follow-up till 5 years. Of note, the S-CMR examination

---

**Table 1: Characteristics of defined studies regarding the diagnostic performance of stress perfusion cardiovascular magnetic resonance.**

| Author                  | Reference                               | N  | Sensitivity (%) | Specificity (%) | Year |
|-------------------------|-----------------------------------------|----|----------------|-----------------|-----|
| Schwitter et al. [31]   | S-CMR vs. ICA                           | 48 | 87%            | 85%             | 2001|
| Nandalur et al. [32]    | S-CMR vs. ICA (meta-analysis)           | 1183| 91%            | 81%             | 2007|
| Schwitter et al. [33]   | S-CMR and SPECT vs. ICA                 | 234| 67%            | 85%             | 2008|
| Greenwood et al. [36]   | S-CMR and SPECT vs. ICA                 | 752| 86%            | 83%             | 2012|
| Schwitter et al. [35]   | S-CMR and SPECT vs. ICA                 | 533| 75%            | 59%             | 2013|
| Greenwood et al. [37]   | S-CMR and SPECT vs. ICA                 | 235| 88%            | 83%             | 2014|
| Takx et al. [41]        | S-CMR vs. FFR-ICA (meta-analysis)       | 798| 89%            | 87%             | 2015|
| Danad et al. [38]       | S-CMR vs. FFR-ICA (meta-analysis)       | 3788| 90%           | 94%             | 2017|
| Pontone et al. [42]     | S-CMR vs. FFR-ICA (meta-analysis)       | 1085| 87%           | 88%             | 2019|

S-CMR: stress cardiovascular magnetic resonance; ICA: invasive coronary angiography; SPECT: single-photon emission computed tomography; FFR-ICA: fractional flow reserve derived from invasive coronary angiography.
included a multiparametric protocol with rest and stress (adenosine) perfusion, cine imaging, 3D coronary MR angiography, and LGE. In this study, Greenwood et al. demonstrated a significantly higher sensitivity and negative predictive value of S-CMR compared to SPECT (86% vs. 66%, 90% vs. 79%, respectively, \( p < 0.0001 \)), but with similar specificity and positive predictive values (83% vs. 82%, 77% vs. 71%, respectively, \( p = 0.916 \) and \( p = 0.061 \)) for detecting significant coronary artery stenosis. Furthermore, S-CMR showed a higher AUC than SPECT (0.89 versus 0.79; \( p < 0.0001 \)) independently of the threshold used to define the presence of obstructive CAD (50% or 70% coronary artery stenosis) and regardless of the extension of vessel disease [36].

In detail, a subsequent gender-based subanalysis of the CE-MARC trial showed greater sensitivity of S-CMR than SPECT in both genders, and differently from SPECT, there were no relevant gender differences in the diagnostic accuracy [37].

Different meta-analyses have also evaluated the diagnostic accuracy of S-CMR in identifying CAD by using invasive FFR as reference standard.

In a meta-analysis by Danad et al., S-CMR had the highest performance for the diagnosis of hemodynamically significant CAD on both a per-vessel (AUC 0.97) and per-patient (AUC 0.94) basis, due to excellent sensitivity and specificity. Anatomical evaluation with CCTA and ICA yielded lower specificity, with functional assessment of coronary atherosclerosis by stress echo, SPECT, and FFR-CT improving accuracy [38].

Other data from meta-analyses showed that S-CMR sensitivities and specificities ranged between 89% and 91% and 81% and 86%, respectively [39–41].

Pontone et al. in 2019 compared the diagnostic performance of noninvasive tests using invasive FFR as a reference standard for CAD, including 77 studies. S-CMR showed a higher sensitivity in detecting functionally significant CAD (81%) than stress perfusion CT combined with CCTA (79%), stress perfusion CT (77%), stress echo (72%), and SPECT (64%), despite being inferior to CCTA (88%), FFR-CT (85%), and PET (85%). However, S-CMR showed a higher test performance to identify patients that needed subsequent invasive coronary artery procedures (91%) [42].

Of note, the majority of studies on the diagnostic performance of S-CMR have been performed on adenosine perfusion stress tests, which actually represent the mainstay of S-CMR.

Little scientific evidence exists on other vasodilator agents, such as dipyridamole and regadenoson. Compared to adenosine, dipyridamole demonstrated reduced sensitivity (86% versus 90%; \( p = 0.022 \)) and similar specificity (77% versus 81%; \( p = 0.065 \)) for diagnosing coronary stenosis \( \geq 50\% \) on ICA, but provided additional information by evaluating both perfusion and wall motion abnormalities [43].

Regadenoson and adenosine achieved equivalent vasodilator stress and myocardial perfusion reserve (MPR), but the latter is cheaper and better tolerated [44, 45].

Regarding dobutamine as a stress agent, although it is the only technique that has offered a comparative performance against dobutamine stress echocardiography [46], it is still less used than vasodilator stressors that allow a simpler and safer vasodilatory myocardial perfusion. In a meta-analysis of 37 studies involving 2191 patients, dobutamine-induced RWMA demonstrated a sensitivity of 0.83 and a specificity of 0.86 on the patient level for revealing angiographically significant CAD (luminal stenosis \( \geq 50\% \)), with higher specificity when assessed on the vessel level (0.93) [32]. However, the diagnostic accuracy of wall motion abnormalities induced by dobutamine S-CMR is significantly influenced by LV geometry, with the lowest performance in patients with increased LV concentricity compared to those with normal geometry and eccentric hypertrophy (0.73 versus 0.87 versus 0.90, respectively) in detecting coronary stenosis \( \geq 70\% \) [47]. All these data have provided a defined role of S-CMR in the diagnosis of known or suspected CAD, with a high accuracy in relation to both coronary artery assessment and functional examinations, in particular SPECT.

4. Prognostic Role of Stress CMR

To allow appropriate management of CAD patients, a reliable prognostic assessment with information on patient outcome should be provided.

4.1. Myocardial Ischemia. Functional evidence of ischemia remains the major criterion for prognostically relevant CAD [48–50]. In 2011, a study by Krittayaphong et al. assessed the prognostic value of combined myocardial perfusion CMR and LGE, thus identifying myocardial ischemia as the strongest predictor for hard cardiac events and major adverse cardiac events (MACE) among patients with known or suspected CAD [51]. Buckert et al. in a large, consecutive, and thereby unselected population of patients presenting with stable angina pectoris reported how patients with reversible perfusion defects significantly showed more cardiac deaths (\( p < 0.0001 \)) and nonfatal myocardial infarction (\( p = 0.001 \)) than in the control group. Again, myocardial ischemia resulted as the strongest independent predictor for adverse events, with a high negative predictive value in the absence of a perfusion deficit [52]. Recently, Heitner et al., in a multicentre study involving 9151 patients followed up for up to 10 years, demonstrated that patients with positive perfusion S-CMR tests had significantly higher annual mortality rates, compared to those with normal tests. Additionally, there was a relevant improvement in predicting adverse events (\( p < 0.001 \)) when positive perfusion S-CMR was included as a variable in Cox regression models [53].

Currently, the exact definition of ischemic burden and thresholds for initiating revascularization remains a subject of considerable interest, since the extent of ischemia was proved to be directly related to the number of subsequent CAD events [54]. Observational data indicated that medical therapy alone may be associated with a reduced risk of death compared with revascularization in patients with less extensive ischemia (<10% of the myocardium), while a more severe ischemia extent (≥10% of the myocardium) demonstrated a reduced risk of CAD and all-cause death with
coronary revascularization compared with medical therapy [55]. A threshold of ≥10% ischemic myocardium was identified to define treatment effectiveness [56]. In 2017, Vincenti et al. performed a prospective study in 1024 patients with known or suspected CAD who were referred for perfusion CMR to detect myocardial ischemia. Data evidenced how an ischemia burden involving ≥1 ischemic segments was the strongest predictor of hard clinical events, and the authors concluded that patients with zero or 1 ischemic segment could be safely deferred to revascularization [57]. Concerning the ischemia extent, a technical advantage of S-CMR over SPECT relies on its higher spatial resolution (3 mm × 3 mm vs. 10 mm × 10 mm in-plane spatial resolution), which allows recording of smaller myocardial areas of hypoperfusion resulting in an even better diagnostic performance [58].

Recently, the MR-INFORM study has suggested S-CMR as a selection criterion for patients to be initiated to revascularization. This is a large, multicentre, randomized controlled clinical effectiveness trial that randomized 918 patients with suspected CAD to a myocardial perfusion CMR-based strategy or an FFR-based strategy. In the results, S-CMR was associated with a significantly higher reduction of invasive revascularization procedures than FFR (35.7% vs. 45.0%, \( p = 0.005 \)), while the percentage of patients free from angina at 12 months did not differ significantly between the two groups (49.2% for S-CMR versus 43.8% for FFR, \( p = 0.21 \)), thus representing noninferiority of S-CMR versus FFR in predicting MACE [59].

4.2. LGE and EF%. Another advantage of S-CMR is based on its ability to give complementary information on cardiac function and myocardial viability, eventually supported by advanced deep learning-based analysis methods [60], which could additionally provide prognostic information [61].

Low left ventricular ejection fraction (LVEF) has traditionally represented a marker of poor outcome in post-MI patients, with LVEF ≤ 35% denoting high-risk patients who require more aggressive management [62]. Moreover, the prognostic role of LGE in the field of CAD has also been extensively assessed [63]. In a retrospective, multicentre study by Kwong et al. in 2019, among 2349 patients with stable chest pain, the absence of LGE, as well as of myocardial ischemia, was related to a low incidence of cardiac events (<1%), reduced need for coronary revascularization (1-3%), and low spending on subsequent ischemia follow-up [64]. Among STEMI patients, early or deferred CMR provided similar high accuracy in detecting segmental and global impaired myocardial perfusion and may help discriminate diagnosis in particular cases such as multivessel coronary disease, microvascular dysfunction, or suspicion of inadequate vasodilator response [68, 69].

Newer techniques allow direct quantification of the signal from the myocardium during first-pass perfusion and reflect the absolute value of myocardial blood flow in each pixel of the image data. Different approaches such as the Fermi model, uptake model, 1-compartment model, model-independent deconvolution method, and 2 model-independent methods have been proposed and have been shown to have similar diagnostic performance [70]. They would advantageously permit fully automated workflow, pixel-wise flow calculation, single-bolus contrast injection, and rapid processing, allowing an easier performable quantitative analysis [71, 72].

Only few studies provide comparative data among commonly used vasodilator agents regarding their hyperaemic effect. Vasu et al. determined the vasodilator power of each stress agent through both rest and stress myocardial blood flow (MBF) quantification [44]. In this analysis, regadenoson showed a higher stress MBF than adenosine and dipyridamole (3.58 vs. 2.81 vs. 2.78 ml/min/g, respectively, \( p < 0.001 \)), with equivalent vasodilator effect to adenosine (37.8 vs. 36.6 μl/sec/g, \( p = NS \)) but with a persistent higher effect than dipyridamole (37.8 vs. 32.6 μl/sec/g, \( p = 0.03 \)) when corrected for heart rate. Therefore, based on quantitative data, a comparable hyperaemic effect of all stress agents could not be fairly assumed. Indeed, most recently Kotecha et al. demonstrated how direct quantification of MBF itself in adenosine stress studies provides a more accurate evaluation of hyperaemia than traditional splenic switch-off and blood pressure response [73], thus encouraging further comparison among stress agents in larger and randomized studies through MBF and coronary flow quantification.
5.2. Mapping Sequences. Multiple studies have enhanced the increasing role of additional mapping sequences in CMR protocols, and potentially, the application of mapping sequences may help detect myocardial ischemia [74]. Stress native T1-mapping T2-mapping could potentially target changes in native myocardial T1 values under vasodilation stress (“T1 reactivity”), which reflect alterations in myocardial blood volume consequent to inducible ischemia [75, 76]. However, currently little evidence exists to allow an affordable use of these sequences in S-CMR protocols, which is still under research.

5.3. Feature-Tracking Analysis. Strain analysis has been lastly demonstrated to provide useful information on the presence of ischemia and on patient outcome in S-CMR studies. As widely evidenced, myocardial strain imaging allows quantification of subtle changes of LV function that typically precede a reduction in LVEF [77]. Garg et al. in 2018 provided the first evidence that a reduction in global longitudinal strain (GLS) at peak myocardial hyperaemic stress could be related to the presence of a perfusion defect in patients with suspected CAD [78]. Eventually a protocol of S-CMR may be integrated with strain analysis, without even significantly prolonging overall time acquisition, as shown in Figure 2.

Interestingly, Palmisano et al. evaluated both adenosine S-CMR mapping and strain data in 28 patients with refractory angina who underwent a coronary sinus Reducer implantation. After implantation, myocardial perfusion along with longitudinal (−16 to −19%; \( p = 0.0192 \)) and circumferential strain (−18 to −21%; \( p = 0.0017 \)) improved, without significant changes in radial, circumferential, and longitudinal strain rate (\( p > 0.05 \)) and native T1 and extracellular volume (ECV) [79]. Advantages of both native mapping and feature tracking could relate to the possibility of achieving a sensitive, noninvasive, quantitative measure of myocardial ischemia and tissue alterations, even without the need for contrast agents, which is desirable due to increasing age and frequent concomitant renal disease in CAD patients. Poli et al. have tested the feasibility and reliability of noncontrast adenosine S-CMR T1 mapping in 58 patients under haemodialysis treatment and proved excellent test-retest reliability of rest and stress native T1 [80].

More scientific evidence is needed to prove the diagnostic performance and risk stratification power of such quantitative approaches. If these become more feasible and robust, they will potentially impact routine CAD management.

6. Current Challenges of Stress CMR

6.1. Main Limitations. A major challenge of S-CMR in clinical practice relies on its limited spatial coverage (only three short-axis slices) in perfusion studies, which may miss the presence of disease, compared to PET [81]. Perfusion S-CMR also has reduced applicability in patients with cardiac devices, which are increasingly prevalent, often due to large susceptibility artefacts that significantly impact image quality, especially in perfusion studies [82]. Moreover, S-CMR provides limited direct coronary stenosis analysis with nonlinear relationship between blood flow and tracer as well as between tracer and image signal has been proved, with contrast agent nonlinearity further affecting myocardial ischemia quantification [83].

Although S-CMR is commonly known as a safe technique due to its nonionizing effect, recent discussion has been raised on the potential acute effect on leucocyte DNA in 1.5 T CMR studies. In a recent paper by Critchley et al., CMR was demonstrated in both in vivo and in vitro studies not to cause DNA double-strand breaks and not to cause loss of leucocyte activity in vitro. However, CMR caused a relevant reduction of leucocytes viability in vitro [84]. All these results might raise suspicion for new detrimental effects of CMR, but larger clinical studies should be provided to prove the clinical impact of the described phenomenon.
6.2. Comparison with Other Imaging Modalities Assessing Myocardial Ischemia. The greatest applicability of CCTA in relation to myocardial ischemia is based on its high spatial resolution with precise evaluation of coronary stenosis and plaque characterization, as outlined in a recent Consensus Statement [85]. However, disadvantages of CCTA regard the use of ionizing radiation, limited temporal resolution, and low contrast-to-noise ratio, which may affect image quality together with beam and scatter artefacts [86].

PET represents the current technical standard for quantitative perfusion imaging, and recently introduced tracers and 13N-ammonia cyclotrons have improved its clinical applicability and cost-effectiveness [87]. Despite its technical appropriateness for assessment of myocardial ischemia, PET is currently limited by reduced availability and lower spatial resolution in comparison to S-CMR [88]. A hybrid PET-CT approach may allow a more comprehensive study of complex diseases, such as multivessel CAD [85]. In opposition, SPECT is widely available in clinical practice and represents the most frequently used modality for perfusion imaging. Due to recent technological evolution, such as the introduction of new dedicated cameras and compartment modeling, absolute values of MBF may be provided by SPECT with improved sensitivity, even in patients with high BMI, previously considered challenging [89]. However, SPECT is also an ionizing technique, with lower spatial resolution and lower image quality with need for attenuation and motion correction [90]. Stress echocardiography provides a rapid, widely available, nonionizing evaluation of myocardial ischemia, with potential for bedside applications. But despite its clinical usefulness, stress echocardiography is not applicable for coronary stenosis severity analysis and actually lacks in automated quantification of perfusion studies [91].

In conclusion, all these imaging modalities present different advantages and disadvantages for myocardial perfusion assessment, and the best clinical practice should be based on the choice of the most appropriate test for each clinical presentation, disease stage, and centre expertise and availability.

6.3. Future Perspectives. Current challenges and limitations of S-CMR will potentially be overcome in the next future thanks to technical evolutions involving both study acquisition and postprocessing phases, eventually leading to less time-consuming and more cost-effective studies.

For example, multitasking CMR has been defined in a study by Christodoulou et al. as a motion-resolved imaging modality with multitime dimensions that can adequately perform quantitative studies based on T1 and T2 relaxation constants without need for cardiac and/or breathing synchronization [92]. This may represent a future direction for CMR and possibly also for stress studies, by providing complete dataset of first-pass time-resolved native T1 mapping perfusion together with quantitative information on oedema and fibrosis within a single sequence.

Another appraisal should be outlined on the evolving role of deep-learning algorithms for fully automated quantification of CMR data [93], possibly supported by supervision with a rapid and high-quality confirmation of clinical images [94].

7. Conclusions

Accurate and informative diagnostic capability and prognostic relevance are essential requirements for patient management in the context of CAD, as underlined by the recent 2019 ESC guidelines on CCS. Among the available diagnostic modalities, S-CMR showed an overall high sensitivity and specificity for the detection of anatomically significant CAD (90% and 80%, respectively) and functionally significant CAD (89% and 87%, respectively). Appropriate selection of patients who undergo S-CMR potentially provides further strength to its diagnostic accuracy, which has been widely validated in a large body of evidence and more recently demonstrated clinical effectiveness in direct guiding revascularization in the presence of myocardial ischemia. Moreover, S-CMR achieves valuable prognostic information that ranges from the extent of myocardial ischemia itself and presence and transmurality of myocardial scarring to the entity of left ventricular remodelling and the impact on systolic function.

Finally, future data on quantitative, objective, and sensitive parameters are expected to yield additional strength to S-CMR in a real-world setting, thus delivering measurements that are accurate and highly reproducible. Given its safety and multiparametric assessment both in terms of diagnosis and prognosis among CAD patients, S-CMR represents an invaluable modality for validating the efficacy of treatment as well as monitoring disease progress. However, despite being a powerful tool, more evidence is needed, especially for quantitative data, to directly translate S-CMR results into routine clinical practice and to provide greater feasibility of a customized patient-tailored approach.

Data Availability

The scientific data supporting this review article are from previously reported studies and datasets, which have been cited. The processed data are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no conflict of interest.

References

[1] M. R. Patel, E. D. Peterson, D. Dai et al., “Low diagnostic yield of elective coronary angiography,” New England Journal of Medicine, vol. 362, no. 10, pp. 886–895, 2010.

[2] SCOT-HEART Investigators, “CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label parallel-group, multicentre trial,” The Lancet, vol. 385, no. 9985, pp. 2383–2391, 2015.

[3] A. I. Guaricci, G. Pontone, L. Fusini et al., “Additional value of inflammatory biomarkers and carotid artery disease in prediction of significant coronary artery disease as assessed by coronary computed tomography angiography,” European Heart Journal-Cardiovascular Imaging, vol. 18, no. 9, pp. 1049–1056, 2017.

[4] A. I. Guaricci, T. Arcadi, N. D. Brunetti et al., “Carotid intima media thickness and coronary atherosclerosis linkage in...
symptomatic intermediate risk patients evaluated by coronary computed tomography angiography,” International Journal of Cardiology, vol. 176, no. 3, pp. 988–993, 2014.

[5] G. D. Aquaro, G. di Bella, S. Castelletti et al., “Clinical recommendations of cardiac magnetic resonance, part I: ischemic and valvular heart disease: a position paper of the working group ‘Applicazioni della Risonanza Magnetica’ of the Italian Society of Cardiology,” Journal of Cardiovascular Medicine, vol. 18, no. 4, pp. 197–208, 2017.

[6] A. I. Guaricci, N. D. Brunetti, M. P. Marra, G. Tarantini, M. di Biase, and G. Pontone, “Diagnosis and prognosis of ischemic heart disease: the framework of cardiac magnetic resonance,” Journal of Cardiovascular Medicine, vol. 16, no. 10, pp. 653–662, 2015.

[7] A. Kiaos, I. Tziatzios, S. Hadjimiltiades, C. Karvounis, and T. D. Karamitcos, “Diagnostic performance of stress perfusion cardiac magnetic resonance for the detection of coronary artery disease: a systematic review and meta-analysis,” International Journal of Cardiology, vol. 252, pp. 229–233, 2018.

[8] J. Knutti, H. Ballo, L. E. Juarez-Orozco et al., “The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability,” European Heart Journal, vol. 39, no. 35, pp. 3322–3330, 2018.

[9] J. Knutti, W. Wijns, A. Saraste et al., “2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes,” European Heart Journal, vol. 41, no. 3, pp. 407–477, 2020.

[10] D. Neglia, D. Rovai, C. Caselli et al., “Detection of significant coronary artery disease by noninvasive anatomical and functional imaging,” Circulation: Cardiovascular Imaging, vol. 8, no. 3, 2015.

[11] C. M. Kramer, J. Barkhausen, C. Bucciarelli-Ducci, S. D. Flamm, R. J. Kim, and E. Nagel, “Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update,” Journal of Cardiovascular Magnetic Resonance, vol. 22, no. 1, p. 17, 2020.

[12] L. Belardinelli, L. C. Shryock, S. Snowdy et al., “The A2A adenosine receptor mediates coronary vasodilation,” Journal of Pharmacology and Experimental Therapeutics, vol. 284, no. 3, pp. 1066–1073, 1998.

[13] J. R. Arnold and G. P. McCann, “Cardiovascular magnetic resonance: applications and practical considerations for the general cardiologist,” Heart, vol. 106, no. 3, pp. 174–181, 2020.

[14] G. Pontone, D. Andreini, A. I. Guaricci et al., “The STRATEGY study (stress cardiac magnetic resonance versus computed tomography coronary angiography for the management of symptomatic revascularized patients): resources and outcomes impact,” Circulation: Cardiovascular Imaging, vol. 9, no. 10, 2016.

[15] Task Force Members, G. Montalescot, U. Schentem et al., “2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology,” European Heart Journal, vol. 34, no. 38, pp. 2949–3003, 2013.

[16] P. S. Douglas, U. Hoffmann, M. R. Patel et al., “Outcomes of anatomical versus functional testing for coronary artery disease,” New England Journal of Medicine, vol. 372, no. 14, pp. 1291–1300, 2015.

[17] G. Pontone, A. Baggiano, D. Andreini et al., “Stress computed tomography perfusion versus fractional flow reserve CT derived in suspected coronary artery disease: the PERFECTION study,” JACC: Cardiovascular Imaging, vol. 12, 8 Part 1, pp. 1487–1497, 2019.

[18] N. Carrabba, A. Migliorini, S. Pradella et al., “Old and new NICE guidelines for the evaluation of new onset stable chest pain: a real world perspective,” BioMed Research International, vol. 2018, Article ID 3762305, 7 pages, 2018.

[19] W. J. Stuijfzand, A. R. van Rosendael, F. Y. Lin et al., “Stress myocardial perfusion imaging vs coronary computed tomographic angiography for diagnosis of invasive vessel-specific coronary physiology: predictive modeling results from the computed tomographic evaluation of atherosclerotic determinants of myocardial ischemia (CREDENcE) trial,” JAMA Cardiology, vol. 5, no. 12, pp. 1338–1348, 2020.

[20] G. Pontone, P. Carità, M. G. Rabbat et al., “Role of cardiac magnetic resonance imaging in myocardial infarction,” Current Cardiology Reports, vol. 19, no. 10, p. 101, 2017.

[21] M. van Assen, D. J. Kuipers, and J. Schwitter, “MRI perfusion in patients with stable chest-pain,” The British Journal of Radiology, vol. 93, no. 1113, p. 20190881, 2020.

[22] B. de Bruyne, N. H. Pijls, B. Kalesan et al., “Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease,” New England Journal of Medicine, vol. 367, no. 11, pp. 991–1001, 2012.

[23] E. Maffei, C. Martini, C. Tedeschi et al., “Diagnostic accuracy of 64-slice computed tomography coronary angiography in a large population of patients without revascularisation: registry data on the comparison between male and female population,” La Radiologia Medica, vol. 117, no. 1, pp. 6–18, 2012.

[24] G. Pontone, D. Andreini, E. Bertella et al., “Impact of an intracycle motion correction algorithm on overall evaluability and diagnostic accuracy of computed tomography coronary angiography,” European Radiology, vol. 26, no. 1, pp. 147–156, 2016.

[25] A. Baggiano, L. Fusini, A. Del Torto et al., “Sequential strategy including FFRCT plus stress-CTP impacts on management of patients with stable chest pain: the Stress-CTP RIPCORD study,” Journal of Clinical Medicine, vol. 9, no. 7, p. 2147, 2020.

[26] N. Gaibazzi, C. Reverberi, A. Squeri, G. De Iaco, D. Ardissino, and T. Gherli, “Contrast stress echocardiography for the diagnosis of coronary artery disease in patients with chest pain but without acute coronary syndrome: incremental value of myocardial perfusion,” Journal of the American Society of Echocardiography, vol. 22, no. 4, pp. 404–410, 2009.

[27] A. I. Guaricci, N. Carrabba, G. D. Aquaro et al., “Advanced imaging techniques (CT and MR): gender-based diagnostic work-up in ischemic heart disease!,” International Journal of Cardiology, vol. 286, pp. 234–238, 2019.

[28] G. Mucogiuiri, M. Chiesa, M. Trotta et al., “Performance of a deep learning algorithm for the evaluation of CAD-RADS classification with CCTA,” Atherosclerosis, vol. 294, no. p, pp. 25–32, 2020.

[29] G. Pontone, D. Andreini, A. Baggiano et al., “Functional relevance of coronary artery disease by cardiac magnetic resonance and cardiac computed tomography: myocardial perfusion and fractional flow reserve,” BioMed Research International, vol. 2015, Article ID 297696, 2015.

[30] A. Baggiano, M. Guglielmo, G. Mucogiuiri, A. I. Guaricci, A. Del Torto, and G. Pontone, “(Epicardial and microvascular) angiogenesis or atypical chest pain: differential diagnoses with cardiovascular magnetic resonance,” European Heart Journal Supplements, vol. 22, Supplement_E, pp. E116–E120, 2020.
[31] J. Schwitter, D. Nanz, S. Kneifel et al., “Assessment of myocardial perfusion in coronary artery disease by magnetic resonance: a comparison with positron emission tomography and coronary angiography,” *Circulation*, vol. 103, no. 18, pp. 2230–2235, 2001.

[32] K. R. Nandalur, B. A. Dwamena, A. F. Choudhri, M. R. Nanda-lur, and R. C. Carlos, “Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease: a meta-analysis,” *Journal of the American College of Cardiology*, vol. 50, no. 14, pp. 1343–1353, 2007.

[33] J. Schwitter, C. M. Wacker, A. C. van Rossum et al., “MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial,” *European Heart Journal*, vol. 29, no. 4, pp. 480–489, 2008.

[34] for the MR-IMPACT investigators, J. Schwitter, C. M. Wacker et al., “Superior diagnostic performance of perfusion-cardiovascular magnetic resonance versus SPECT to detect coronary artery disease: the secondary endpoints of the multicenter multivendor MR-IMPACT II (magnetic resonance imaging for myocardial perfusion assessment in coronary artery disease trial),” *Journal of Cardiovascular Magnetic Resonance*, vol. 14, no. 1, 2012.

[35] J. Schwitter, C. M. Wacker, N. Wilke et al., “MR-IMPACT II: magnetic resonance imaging for myocardial perfusion assessment in coronary artery disease trial: perfusion-cardiac magnetic resonance vs. single-photon emission computed tomography for the detection of coronary artery disease: a comparative multicentre, multivendor trial,” *European Heart Journal*, vol. 34, no. 10, pp. 775–781, 2013.

[36] J. P. Greenwood, N. Maredia, J. F. Younger et al., “Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial,” *Lancet*, vol. 379, no. 9814, pp. 453–460, 2012.

[37] J. P. Greenwood, M. Motwani, N. Maredia et al., “Comparison of cardiovascular magnetic resonance and single-photon emission computed tomography in women with suspected coronary artery disease from the clinical evaluation of magnetic resonance imaging in coronary heart disease (CE-MARC) trial,” *Circulation*, vol. 129, no. 10, pp. 1129–1138, 2014.

[38] I. Danad, J. Szymonifka, J. W. Twisk et al., “Diagnostic performance of cardiac imaging methods to diagnose ischaemia-causing coronary artery disease when directly compared with fractional flow reserve as a reference standard: a meta-analysis,” *European Heart Journal*, vol. 38, no. 13, pp. 991–998, 2017.

[39] R. R. Desai and S. Jha, “Diagnostic performance of cardiac stress perfusion MRI in the detection of coronary artery disease using fractional flow reserve as the reference standard: a meta-analysis,” *American Journal of Roentgenology*, vol. 201, no. 2, pp. W245–W252, 2013.

[40] M. Li, T. Zhou, L. F. Yang, Z. H. Peng, J. Ding, and G. Sun, “Diagnostic accuracy of myocardial magnetic resonance perfusion to diagnose ischemic stenosis with fractional flow reserve as reference: systematic review and meta-analysis,” *JACC: Cardiovascular Imaging*, vol. 7, no. 11, pp. 1098–1105, 2014.

[41] R. A. P. Takx, B. A. Blomberg, H. El Aidi et al., “Diagnostic accuracy of stress myocardial perfusion imaging compared to invasive coronary angiography with fractional flow reserve meta-analysis,” *Circulation: Cardiovascular Imaging*, vol. 8, no. 1, 2015.

[42] G. Pontone, A. I. Guaricci, S. C. Palmer et al., “Diagnostic performance of non-invasive imaging for stable coronary artery disease: a meta-analysis,” *International Journal of Cardiology*, vol. 300, pp. 276–281, 2020.

[43] M. Hamon, G. Fau, G. Née, J. Ehtisham, and R. Morello, “Meta-analysis of the diagnostic performance of stress perfusion cardiovascular magnetic resonance for detection of coronary artery disease,” *Journal of Cardiovascular Magnetic Resonance*, vol. 12, no. 29, 2010.

[44] S. Vasu, W. P. Bandettini, L.-Y. Hsu et al., “Regadenoson and adenosine are equivalent vasodilators and are superior than dipyridamole: a study of first pass quantitative perfusion cardiovascular magnetic resonance,” *Journal of Cardiovascular Magnetic Resonance*, vol. 15, no. 1, p. 85, 2013.

[45] H. L. Brink, J. A. Dickerson, J. A. Stephens, and K. K. Pickworth, “Comparison of the safety of adenosine and regadenoson in patients undergoing outpatient cardiac stress testing,” *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, vol. 35, no. 12, pp. 1117–1123, 2015.

[46] E. Nagel, H. B. Lehmkuhl, W. Bocksch et al., “Noninvasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI: comparison with dobutamine stress echocardiography,” *Circulation*, vol. 99, no. 6, pp. 763–770, 1999.

[47] R. Gebker, J. G. Mirelis, C. Jahnke et al., “Influence of left ventricular hypertrophy and geometry on diagnostic accuracy of wall motion and perfusion magnetic resonance during dobutamine stress,” *Circulation: Cardiovascular Imaging*, vol. 3, no. 5, pp. 507–514, 2010.

[48] E. Maffei, S. Seiun, C. Martini et al., “Prognostic value of computed tomography coronary angiography in patients with chest pain of suspected cardiac origin,” *La Radiologia Medica*, vol. 116, no. 5, pp. 690–705, 2011.

[49] A. I. Guaricci, V. Lorenzoni, M. Guglielmo et al., “Prognostic relevance of subclinical coronary and carotid atherosclerosis in a diabetic and nondiabetic asymptomatic population,” *Clinical Cardiology*, vol. 41, no. 6, pp. 769–777, 2018.

[50] N. Gaibazzi, T. Porter, V. Lorenzoni et al., “Effect of coronary revascularization on the prognostic value of stress myocardial contrast wall motion and perfusion imaging,” *Journal of the American Heart Association*, vol. 6, no. 6, article e006202, 2017.

[51] R. Krittayaphong, V. Chaitiraphan, A. Maneesai, and S. Udompanturak, “Prognostic value of combined magnetic resonance myocardial perfusion imaging and late gadolinium enhancement,” *The International Journal of Cardiovascular Imaging*, vol. 27, no. 5, pp. 705–714, 2011.

[52] D. Buckert, P. Dewes, T. Walcher, W. Rottbauer, and P. Bernhardt, “Intermediate-term prognostic value of reversible perfusion deficit diagnosed by adenosine CMR: a prospective follow-up study in a consecutive patient population,” *JACC: Cardiovascular Imaging*, vol. 6, no. 1, pp. 56–63, 2013.

[53] J. F. Heitner, R. J. Kim, H. W. Kim et al., “Prognostic value of vasodilator stress cardiac magnetic resonance imaging: a multicenter study with 48 000 patient-years of follow-up,” *JAMA Cardiology*, vol. 4, no. 3, pp. 256–264, 2019.

[54] M. Kolentinis, M. Le, E. Nagel, and V. O. Punzmann, “Contemporary cardiac MRI in chronic coronary artery disease,” *European Cardiology Review*, vol. 15, article e50, 2020.
[55] R. Hachamovitch, A. Rozanski, L. J. Shaw et al., “Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy,” *European Heart Journal*, vol. 32, no. 8, pp. 1012–1024, 2011.

[56] R. Hachamovitch, S. W. Hayes, J. D. Friedman, I. Cohen, and D. S. Berman, “Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography,” *Circulation*, vol. 107, no. 23, pp. 2900–2907, 2003.

[57] G. Pontone, A. I. Guaricci, D. Andreini et al., “Prognostic value of dipyridamole stress cardiac magnetic resonance in patients with known or suspected coronary artery disease: a mid-term follow-up study,” *European Radiology*, vol. 26, no. 7, pp. 2155–2165, 2016.

[58] P. Ponikowski, A. A. Voors, S. D. Anker et al., “Acute and chronic heart failure of the European Society of Cardiology,” *European Heart Journal*, vol. 32, no. 1, pp. 505–537, 2011.

[59] S. Yimcharoen, S. Zhang, Y. Kaolawanich, P. Tanapibunpon, L. Afonso, and R. Krittayaphong, “State-of-the-art review: stress T1 mapping—technical considerations, pitfalls and emerging clinical applications,” *Magnetic Resonance Materials in Physics, Biology and Medicine*, vol. 10, no. 5, pp. 526–537, 2019.

[60] P. G. Masci, A. G. Pavon, G. Pontone et al., “Early or deferred cardiovascular magnetic resonance after ST-segment–chest pain,” *European Heart Journal - Cardiovascular Imaging*, vol. 21, no. 1, pp. 1024, 2011.

[61] S. Pica, G. Di Giovine, M. Bollati et al., “Magnetic resonance imaging for ischaemia and viability detection. Guiding patient selection to revascularization in coronary chronic total occlusions: the CARISMA_CTO study design,” *International Journal of Cardiology*, vol. 272, pp. 356–362, 2018.

[62] R. Y. Kwong, Y. Ge, K. Steel et al., “Cardiac magnetic resonance stress perfusion imaging for evaluation of patients with chest pain,” *Journal of the American College of Cardiology*, vol. 74, no. 14, pp. 1741–1755, 2019.

[63] P. G. Masci, A. G. Pavon, G. Pontone et al., “Early or deferred cardiovascular magnetic resonance after ST-segment–myocardial infarction for effective risk stratification,” *European Heart Journal - Cardiovascular Imaging*, vol. 21, no. 6, pp. 632–639, 2020.

[64] G. Pontone, D. Andreini, E. Bertella et al., "Prognostic value of dipyridamole stress cardiac magnetic resonance in patients with known or suspected coronary artery disease: a mid-term follow-up study," *European Radiology*, vol. 26, no. 7, pp. 2155–2165, 2016.

[65] J. Schulz-Menger, D. A. Bluemke, J. Bremerich et al., “Standardized image interpretation and post-processing in cardiovascular magnetic resonance - 2020 update: Society for Cardiovascular Magnetic Resonance (SCMR): Board of Trustees Task Force on Standardized Post-Processing,” *Journal of Cardiovascular Magnetic Resonance*, vol. 22, no. 1, p. 19, 2020.

[66] G. Morton, A. Chiribiri, M. Ishida et al., “Quantification of absolute myocardial perfusion in patients with coronary artery disease: comparison between cardiovascular magnetic resonance and positron emission tomography,” *Journal of the American College of Cardiology*, vol. 60, no. 16, pp. 1546–1553, 2012.

[67] T. Quinaglia, M. Jerosch-Herold, and O. R. Coelho-Filho, “State-of-the-art quantitative assessment of myocardial ischaemia by stress perfusion cardiac magnetic resonance,” *Magnetic Resonance Imaging Clinics of North America*, vol. 27, no. 3, pp. 491–505, 2019.

[68] J. D. Biglands, D. R. Magee, S. P. Sourbron, S. Plein, J. P. Greenwood, and A. Radjenovic, “Comparison of the diagnostic performance of four quantitative myocardial perfusion estimation methods used in cardiac MR imaging: CE-MARC substudy,” *Radiology*, vol. 275, no. 2, pp. 393–402, 2015.
[79] A. Palmisano, F. Giannini, P. Rancoita et al., “Feature tracking and mapping analysis of myocardial response to improved perfusion reserve in patients with refractory angina treated by coronary sinus Reducer implantation: a CMR study,” The International Journal of Cardiovascular Imaging, vol. 36, 2020.

[80] F. E. Poli, G. S. Gulsin, D. S. March et al., “The reliability and feasibility of non-contrast adenosine stress cardiovascular magnetic resonance T1 mapping in patients on haemodialysis,” Journal of Cardiovascular Magnetic Resonance, vol. 22, no. 1, p. 43, 2020.

[81] R. Manka, L. Wissmann, R. Gebker et al., on behalf of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM), D. Agostini, P. Y. Marie et al., “Performance of cardiac cadmium-zinc-telluride gamma camera imaging in coronary artery disease: a review from the cardiovascular committee of the European Association of Nuclear Medicine (EANM),” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 10, pp. 1887–1902, 2010.

[82] A. G. Christodoulou, J. L. Shaw, C. Nguyen et al., “Magnetic resonance multitascking for motion-resolved quantitative cardiovascular imaging,” Nature Biomedical Engineering, vol. 2, no. 4, pp. 215–226, 2018.

[83] B. Böttcher, E. Beller, A. Busse et al., “Fully automated quantification of left ventricular volumes and function in cardiac MRI: clinical evaluation of a deep learning-based algorithm,” The International Journal of Cardiovascular Imaging, vol. 36, no. 11, pp. 2239–2247, 2020.

[84] Q. Zhang, E. Hann, K. Werys et al., “Deep learning with attention supervision for automated motion artefact detection in quality control of cardiac T1-mapping,” Artificial Intelligence in Medicine, vol. 110, p. 101955, 2020.